ArticleScientific reports2025
The impact of lymphadenectomy on cancerspecific survival in patients with low-grade endometrioid carcinoma of stage T1a.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessing preoperative biopsy accuracy in endometrial carcinoma: A preliminary low- and middle-income country-based report.Biomedical reports · 2026Article
- Predictive value of deep myometrial invasion for lymph node metastasis in low-grade endometrioid carcinoma and its implications for surgical decision-making.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients with low-grade endometrioid carcinoma of stage T1a, the role of lymphadenectomy in staging surgery remains controversial. This study aims to evaluate the impact of lymphadenectomy on cancer-specific survival (CSS) in this patient population using a large, population-based dataset. We conducted a retrospective analysis using the Surveillance, Epidemiology, and End Results (SEER) database, identifying 11,014 patients with stage T1a, low-grade endometrioid carcinoma from 2004 to 2015. Patients were divided into lymphadenectomy and non-lymphadenectomy groups. Propensity score matching (PSM) was performed to balance baseline characteristics. Kaplan-Meier analysis, log-rank tests, and multivariate Cox regression were used to assess CSS and identify independent prognostic factors. Before PSM, the non-lymphadenectomy group had higher CSS compared to the lymphadenectomy group (HR = 1.56, 95% CI: 1.16-2.10, p = .003). After 1:1 PSM, CSS was similar between the two groups (HR = 1.09, 95% CI: 0.78-1.53, p = .605). Subgroup analyses showed no significant differences in CSS except for the subgroup with tumor size > 2 cm, where non-lymphadenectomy was associated with better CSS (HR = 0.50, p = .035). Multivariate Cox regression analysis identified age, marital status, histological grade, and chemotherapy as independent prognostic factors for CSS, while lymphadenectomy was not (p = .980).. Our findings suggest that lymphadenectomy does not improve CSS in patients with low-grade endometrioid carcinoma of stage T1a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.